TY - JOUR
AU - Miles, David
AB - Letter to the Editor Oncology 2004;66:339–340 DOI: 10.1159/000078337 Setting the Record Straight: Activity of Gemcitabine Monotherapy for Breast Cancer a b Peter Reichardt David Miles a b Universitätsklinikum Charité, Berlin, Germany; Cancer Research UK, Breast Biology Group, Guy’s and St. Thomas’ Hospital, London, UK Further to the article by Heinemann [1], he conveniently selected a minimum evalu- grade 3 or 4 neutropenia. A 30% incidence of we would like to highlight some of the less able patient number of 19 for the studies grade 3/4 neutropenia was reported in two favourable trials omitted from this review of included in the review. In their study, only further trials of gemcitabine monotherapy in gemcitabine data and dispute some of the 18 of the 21 patients were evaluable. In this 47 and 44 patients, respectively, with less statements made. The author states that US study, 21 patients with stage IV breast heavily pretreated metastatic breast cancer ‘gemcitabine has proven activity as a well- cancer received gemcitabine 800 mg/m on [9, 10]. The high incidence of myelosuppres- tolerated single agent and even as salvage days 1, 8, and 15 of each 28-day cycle. Once sion with gemcitabine reduces possibilities therapy in intensively pretreated 
TI - Setting the Record Straight: Activity of Gemcitabine Monotherapy for Breast Cancer
JF - Oncology
DO - 10.1159/000078337
DA - 2004-06-01
UR - https://www.deepdyve.com/lp/karger/setting-the-record-straight-activity-of-gemcitabine-monotherapy-for-dNAZy1iQrP
SP - 339
EP - 340
VL - 66
IS - 4
DP - DeepDyve
ER -